Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Grants

Funding Acknowledgements

The Accelerating Medicines Partnership Schizophrenia (AMP SCZ) is a public-private partnership managed by the Foundation for the National Institutes of Health. The AMP SCZ research program is supported by contributions from the AMP SCZ public and private partners, including NIMH (U24MH124629, U01MH124631, and U01MH124639) and Wellcome (220664/Z/20/Z and 220664/A/20/Z). The support of the NHMRC CRE PRE-EMPT (1198304) is acknowledged. The views expressed in this article are personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Department of Health and Human Services, including the National Institutes of Health and the US Food and Drug Administration, the United States Government, or the European Medicines Agency or one of its committees or working parties. AMP SCZ Steering Committee members include Loni Ajagbe, R. Reina Benabou, Lynsey Bilsland, Linda S. Brady, Terri Brister, Florence Butlen-Ducuing, Kenneth Duckworth, Gregory K. Farber, Tiffany Farchione, Bernard A. Fischer, Sophia Frangou, Suzanne T. Garcia, Nitin Gogtay, Joshua A. Gordon, Robert K. Heinssen, Brian R. Johnson, Pushkar S. Joshi, Carlos A. Larrauri, Sarah H. Lisanby, Gahan Pandina, Sharin E. Roth, Michael Sand, Adam Savitz, Vikas Sharma, Brandon Staglin, Alessio Travaglia, Eva Velthorst, and Glen Wunderlich. Other AMP SCZ members not listed elsewhere include Margaret C. Grabb, Daniel Janes, Sarah E. Morris, Jonathan Pevsner, S. Andrea Wijtenburg, Laura M. Rowland, Ming Zhan, Eline Appelmans, Noam I. Keren, and Steven Hyman. S.W.W. has received sponsor-initiated research funding support from Boehringer-Ingelheim, Amarex, and SyneuRx. He has been a paid consultant to Boehringer-Ingelheim, New England Research Institute, and Takeda. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. B.C.W. has been a paid consultant with Boehringer-Ingelheim and the Pier Institute. A.A. holds equity and is a member of the Technology Advisory Board for Neumora Therapeutics, Inc.; is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019. J.M.K has received honoraria for lectures or consulting from Alkermes. R.S.K. has consulted for Alkermes, Otsuka, and Sunovion. D.O.P reports consulting for Alkermes. S.R.C. reports Speaker's Fees/ Honoraria: Janssen-Cillag Australia, Lundbeck-Otsuka Australia, Servier Australia Advisory Board: Lundbeck-Otsuka Australia (Maintena, Brexpiprazole) Investigator-initiated grants: Janssen-Cillag Australia, Lundbeck-Otsuka AustraliaTravel Support: Janssen-Cillag Australia. D.H.M. has served as a consultant for Neurocrine Biosciences. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. E.Y.H.C. reports investigator-initiated grants: Janssen-Cillag. C.M.D.-C. reports grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024), and honoraria from Exeltis and Angelini. P.J.M. has received sponsor-initiated funding from Alkermes, Boehringer-Ingelheim, Roche, NeuroRX, and Otsuka and honorarium from Alkermes, Lundbeck, Otsuka, and BioXcel. B.H.E is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer-Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. Other authors report no conflict of interest. P.F.P has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer-Ingelheim, Proxymm Science, outside the current study. G.P.S. has consulted for Boehringer-Ingelheim, Acadia, Minerva, and Sunovion. J.T. is a scientific Advisor for Precision Mental Wellness. R.U. reports grant funding from Medical Research Council (MR/S037675/1), National Institute for Health Research: Health Technology Assessment (NIHR 127700), and speaker fees from Sunovion, Springer Heathcare, Otuska, and Vitaris outside the submitted work. R.U. holds unpaid officership with the British Association for Pharmacology- Honorary General Secretary 2021-2024 and is Deputy Editor, The British Journal of Psychiatry. J.J. is an employee of Manifest Technologies and has previously worked for Neumora (formerly BlackThorn Therapeutics) and a coinventor on the following patents: Anticevic A, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019. P.A.L. has received honoraria for talks presented at educational meetings organized by Boehringer-Ingelheim. V.H.S. has served on Advisory Boards to Takeda and Karuna Therapeutics. A.T. has been a consultant to or has received honoraria or grants from Janssen Cilag, Otsuka, Pfizer, and Servier. P.P. has received Speaker's Fees from Angelini, Janssen, Lundbeck-Otsuka, and Roche.